Financial News

Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced its entry into a research collaboration with Ironwood Pharmaceuticals, Inc. (“Ironwood’), a commercial biotechnology company, focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and Nicox’s proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new therapeutics for the treatment of certain ophthalmic conditions.

Read more

Nicox to present at the 2018 BIO International Convention

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Emmet Purtill, Senior Director Business Development, will present at the 2018 BIO International Convention on Wednesday June 6, 2018 at 11:15 a.m. Eastern Time. The conference is being held at the Convention & Exhibition Center in Boston.
The presentation will be available on Nicox website (www.nicox.com) in “Presentations &

Read more

Nicox Provides First Quarter 2018 Business and Financial Results

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided an overview of its corporate activities and milestones, as well as revenues and cash position for the Nicox Group as of March 31, 2018.
The early months of 2018 marked a time of growth for Nicox, with the expansion and relocation of our U.S.

Read more
More news